Recombinant Antibody Articles & Analysis
17 news found
Introduction We recently sat down with one of our valued customers, Dr Alexis Rossignol (Clean Cells), to discuss his experience with VIPS PRO, our cutting-edge technology designed to streamline and enhance the early stages of cell line development. This interview provides insight into Clean Cells’ quest to automate and increase single-cell seeding while having undisputable proof ...
The featured speaker will discuss how temperature and osmolality in the cell culture can be optimized, seeking improved monoclonal antibody production efficiency. Over the past two decades, the biopharmaceutical market has expanded, with monoclonal antibodies exhibiting a 26 percent higher approval rate than other drugs. The market value of monoclonal ...
“With advanced facilities, we are capable of providing CMO, CRO, and CDMO services globally for the design, development, and production of various biologic drug products, including but not limited to recombinant proteins, ADCs, monoclonal antibodies, and bispecific antibodies,” said the Marketing Chief of Alfa Chemistry. ...
Creative Diagnostics, a global leader in offering raw materials, antibodies, and reagents for the bio-technology industry, announced the launch of Monkeypox Virus Antigens and Antibodies to support scientists focused on the research of monkeypox virus. ...
He has extensive experience working across various modalities including recombinant proteins, monoclonal antibodies, ADCs, cell therapies and gene therapies. ...
As a global leading supplier of raw materials, antibodies, and reagents for bio-technology industry, Creative Diagnostics recently launches a series of NiV recombinant antigen and antibody pairs. ...
New biotherapeutic glycoproteins, such as recombinant monoclonal antibodies (mAbs), have been widely used to treat many diseases. ...
Business Performance Revenue for the quarter stood at Rs 981 Crore, reporting a growth of 28% YoY, driven by steady sales of our biosimilars portfolio including insulins, monoclonal antibodies (mAbs) and recombinant proteins across developed and emerging markets and a strong performance from our Branded Formulations business in India. ...
ByBiocon
Recent results have confirmed that this drug, IBIO123, is capable of neutralizing SARS-CoV-2 (COVID-19) and all its current variants of concern (VOCs) that have emerged throughout the pandemic, including the latest Omicron variant. IBIO123 is an inhaled antibody-based immunotherapy with an ongoing multisite phase 1 and 2 clinical program for the treatment of symptomatic ...
Quick to Clinic leverages Gibco Freedom ExpiCHO – a royalty-free, high-yield expression system, that can scale seamlessly from an R&D environment – and includes critical activities such as cell line development, process fit, analytical development and qualification, yielding a robust process platform for biopharma companies developing mammalian recombinant ...
INOVIO (NASDAQ: INO), a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today reported financial results for the quarter ended December 31, 2020. INOVIO's management will host a live conference call and webcast at 4:30 p.m. Eastern Standard Time today to discuss ...
Jan ter Meulen is a seasoned biotech executive with broad experience in immuno-oncology, vaccines, recombinant antibodies, and infectious disease R&D, from discovery research through to phase 3 clinical trials. ...
This unique proteomic platform of targets will help Grifols and Alkahest to unlock new therapeutics and diagnostics, develop new plasma proteins, new indications for currently licensed plasma proteins, biomarkers for diagnostics, recombinant proteins and antibodies as well as small-molecule drugs. Understanding the plasma proteome is the key to Alkahest’s ...
Abologix has obtained impressive data with its anti-JAM-C recombinant monoclonal antibody rH225 in an animal Mantle Cell Lymphoma (MCL) NOD/SCID mouse model. ...
ByAbologix
The agreement, facilitated by Johnson & Johnson Innovation LLC, will focus initially on the discovery and development of therapeutic antibodies in oncology. The collaboration will utilize IBio’s proprietary Nebula antibody discovery platform to advance oncology targets that historically have been a challenge for therapeutic development. ...
The potential of the Nebula Platform for generating therapeutics antibodies is huge, and its validation through this project could pave the way for humanized chicken antibodies to be deployed against many cancers and other diseases currently lacking effective treatments,” said Frederic Leduc, CEO of Immune Biosolutions. ...
For example, the ACQUITY UPLC H-Class Bio System is ideally paired with Waters’ new bioseparations technology columns: the ACQUITY UPLC BEH200 SEC column, the first UPLC analytical size-exclusion chromatography (SEC) solution for the characterization of proteins and their aggregates, and the Protein-PakHi Res IEX column, designed for the analysis of biomolecules including monoclonal ...